Se rendre au contenu

Scientific Seminar - Exploring New Drug Modalities From mAbs to Cell & Gene Therapies and Beyond

ANALIS ACADEMY - ONE DAY SEMINAR

Les inscriptions sont clôturées
Ajouter au calendrier :

Thank you for joining our seminar
Special thanks to your speaker for their valuable contributions

SCIENTIFIC SEMINAR

Are your workflows ready for next-generation drug development?

*ATTENTION - seats are limited, register now ! participation is free but registration is required.

Biopharma is evolving fast. 

From monoclonal antibodies to cell & gene therapies, staying ahead means mastering new tools, techniques, and platforms.
That’s why we’re thrilled to invite you to our upcoming Analis Academy Scientific Seminar!

Discover how to optimize your lab for the future of therapeutics:

⚗️Cutting-edge platforms for automated clone screening & EV characterization
🧫 New tools solving bottlenecks in mAb & CGT workflows
🧪  Explore analytical advances, including in capillary electrophoresis for complex drug formats
💡  Keynote insights from leading QC/QA professionals and academic biotech pioneers
🧭  Live demonstrations, networking, and expert one-on-ones with Analis & partners

This is your opportunity to benchmark your lab, explore next-gen analytical instruments, and gain exclusive access to use cases you won’t hear anywhere else.

🚀 Who Should Join?

  • Biotech & Biopharma R&D leaders
  • QC/QA managers in biologics & advanced therapy labs
  • Process development engineers & lab managers
  • Academia-industry translational researchers
  • Scientists evaluating next-gen instrumentation 


As places are limited  and in order to reduce our environmental impact, if you are registered but unable to attend the seminar, please inform us as soon as possible by sending an email to RTE@ANALIS.BE Thank you.


PROGRAM

08.45  - 09.45 

Registration & Welcome coffee


09.45  - 10.00 

Welcome & Introduction : Transforming the Therapeutic Landscape 


10.00 - 10.30

Overcoming Bottlenecks, Using an Automated Clone Screening System for Clone Selection in a mAb - monoclonal Antibody - Workflow

The Cydem VT automated clone screening platform provides a high-throughput, integrated solution for Cell Line Development workflows. Automatization of critical screening steps improves experimental consistency and contributes to the acceleration of biopharmaceutical development timelines.

Anna Kress
Beckman Coulter Manager Applications Science


10.30 - 11.00

Standardizing Plasmid DNA Production: Inline Lysis Meets Single-Step Chromatography for CGT Breakthroughs

Plasmid DNA (pDNA) serves as a critical starting material to produce advanced therapy medicinal products (ATMPs) in the field of cell and gene therapy. The growing demand for pDNA requires the development of manufacturing processes that can meet aggressive timelines while maintaining cost-effectiveness. Here we present a robust single-use platform process that enables seamless scale-up from research and development (R&D) to good manufacturing practice (GMP) grade.

This process involves bacterial cell growth in fermenters, alkaline cell lysis, and a streamlined chromatographic step. A key aspect of this approach is the implementation of a controlled cell lysis step, ensuring the production of high-quality pDNA that complies with regulatory agency standards. Notably, this process achieves efficient purification and polishing with just a single chromatographic step, simplifying the manufacturing process as well as reducing costs.

We will provide an overview of the platform process and share results on the quality attributes obtained through its implementation. Our findings demonstrate the effectiveness of this approach in generating pDNA that meets quality requirements set by regulatory agencies.

Nuria Gomez Santos  

Catalent - Director of Process and Analytical Development


11.00 - 11.15

Coffee break


11.15 - 11.45

Empowering Breakthroughs in CGT with SCIEX Capillary Electrophoresis and Enhanced Detection

SCIEX Capillary Electrophoresis (CE) is a key technology in the analytical toolbox for Cell and Gene Therapy and other emerging modalities, offering high-resolution, reproducible analysis of complex biomolecules. This presentation will highlight critical applications in CGT workflows and introduce a newly launched detection system that enhances sensitivity and performance.

Marcus Heinl  
Sciex - Senior Field Application Specialist


11.45 - 12.15

How Capillary Electrophoresis could be instrumental in the characterisation of rAAVs  - recombinant Adeno-Associated Viruses - in Gene Therapy
Prajakta Mulay  
UCB - Scientist Biophysics method development in Gene therapy


12.15 - 13.15

 Lunch & Networking 


13.15 - 13.45

Extracellular Vesicles – Unlocking Biomedical Potential Through Advanced Separation and Characterization


EVs hold great promise for biomedical applications, but their complexity requires a robust technological toolbox for separation and characterization. My talk will highlight why these techniques are essential for advancing EV research, what they can reveal about EV biology, and how they can accelerate the translation of EVs into diagnostics and therapeutics.


An Hendrix  
Principal investigator & Full professor, Laboratory of Experimental Cancer researcher at UGent - CRIG Group leader - Founder & President of the BESEV -  Scientific supervisor, CORE Extracellular Vesicles (UGent) 


13.45 - 14.15

LNPs - Lipid Nanoparticles  - the high potential drug delivery system of the futureµ


Lipid Nanoparticles (LNPs) are revolutionizing drug delivery, from vaccines to gene therapies. In this presentation, we'll explore the milestones in their discovery and focus on their characterization including Flow Cytometry and Analytical Ultracentrifugation.


Lukas Bialkowski  
BECKMAN COULTER - Bioprocessing market development Manager


14.15 - 14.30

Coffee break


14.30 - 15.00

Integration of complex 2D and 3D cell brain models in Drug Discovery

Advancements in in vitro neuroscience have enabled the development of complex 2D monolayer and 3D organoid-based brain cell models for drug discovery. IPSC cultures allow medium to high-throughput screening and controlled manipulation of cellular phenotypes, while 3D models recapitulate cytoarchitecture, cell-cell interactions, and extracellular matrix dynamics. We describe protocols for generating region-specific brain organoids and co-culture systems, comparative transcriptomic and electrophysiological analyses. This integrative strategy accelerates CNS drug development by bridging the gap between in vitro modeling and clinical translation.

David Moreno 
UCB  -  Director of Cell Translational Sciences


15.00 - 15.30

Automation in Cell & Gene Therapy 
Peter BRAUN 
BECKMAN COULTER - Field-Project Manager - Automation 


15.30- 16.00

Improving the accuracy of Western Blot Imaging for reliable results

Tristan Fromager
VILBER - Application Specialist - Regional Sales Manager


16.00- 16.30

Open discussion and closing session 



Our great panel of Experts & Scientists

Already thanks to our speakers and partners.  Their expertise and insights will make this event a truly high-level and 
inspiring experience for all participant
s

Lukas Bialkowski Beckman Coulter  Bioprocessing market development Manager

Lukas Bialkowski

Beckman Coulter

Bioprocessing market development Manager

Peter Bra​un

Peter Braun
Beckman Coulter

Field-Project Manager - Automation

Tristan Fromager VILBER  Application Specialist

Tristan Fromager

VILBER

Application Specialist
Regional Sales Manager

Nuria Gomez Santos Catalent  Director Process & Analytical Dev -  Cell & Gene Therapies

Nuria Gomez Santos 

Catalent

Director Process & Analytical Dev -

Prof An Hendrix Cancer researcher at UGent - CRIG Group leader - President of BESEV

Prof An Hendrix

Cancer researcher at UGent - CRIG Group leader - President of BESEV


Marcus Heinl​  Sciex  Senior Field Application Specialist

Marcus Heinl

Sciex

Senior Field Application Specialist

Anna Kress Beckman Coulter  Manager Applications Science

Anna Kress

Beckman Coulter

Manager Applications Science

David Moreno UCB  Director of Cell Translational Sciences

David Moreno

UCB

Director of Cell Translational Sciences

Prajakta Mulay

Prajakta Mulay

UCB

Scientist Biophysics method develop. in Gene therapy


 

PROGRAM 

08.30  - 09.15 

 


Registration & Welcome Coffee

 LIVING TOMORROW 
I
ndringingsweg 1, 1800 Vilvoorde 

🚌 Easy access by public transport

www.livingtomorrow.com